Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490345 | 0.91 | NOTUM (0.53) | NOTUMKMT2AELANEPOLBCYP1A2 | |
| SCHEMBL560905 | 0.87 | NOTUM (0.49) | NOTUMKMT2AELANECYP1A2GSR | |
| SCHEMBL5752612 | 0.87 | NOTUM (0.76) | NOTUMELANEPOLBCYP1A2GSR | |
| SCHEMBL29808797 | 0.87 | NOTUM (0.76) | NOTUMELANEPOLBCYP1A2GSR | |
| SCHEMBL31490303 | 0.85 | ELANE (0.48) | NOTUMKMT2AELANECYP1A2GSR | |
| SCHEMBL560944 | 0.85 | ELANE (0.48) | NOTUMKMT2AELANECYP1A2GSR | |
| SCHEMBL8065166 | 0.84 | NOTUM (0.65) | NOTUMKMT2AELANEPOLBCYP1A2 | |
| SCHEMBL560993 | 0.84 | CNR2 (0.52) | NOTUMELANENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL561192 | 0.84 | CNR1 (0.50) | NOTUMELANEALDH1A1 | |
| SCHEMBL31490248 | 0.84 | CNR2 (0.52) | NOTUMELANENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663973-B3 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| EP-1663973-B1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| CN-1882542-B | 2-pyridone derivatives as inhibitors of neutrophil elastase and uses thereof | ASTRAZENECA AB | 2011-11-09 | — | — | CN | disclosed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| CN-1882542-A | 2-pyridone derivatives as inhibitors of neutrophil elastase and uses thereof | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1663973-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026123-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | SERPINB1, ELANE, SERPINE1 | NOTUM 3528/4885KMT2A 4343/4885ELANE 2/4885 |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | NOTUM 3343/4885KMT2A 4262/4885ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.